Chardan Capital Comments on Ocugen FY2025 Earnings

Ocugen, Inc. (NASDAQ:OCGN) – Equities researchers at Chardan Capital issued their FY2025 earnings per share estimates for Ocugen in a note issued to investors on Monday, March 24th. Chardan Capital analyst D. Gataulin expects that the company will post earnings per share of ($0.25) for the year. Chardan Capital has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Ocugen’s current full-year earnings is ($0.20) per share. Chardan Capital also issued estimates for Ocugen’s FY2026 earnings at ($0.27) EPS.

Ocugen (NASDAQ:OCGN) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.05) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.05). The company had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. Ocugen had a negative return on equity of 154.75% and a negative net margin of 532.51%. During the same period last year, the firm posted ($0.03) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Ocugen in a report on Thursday, March 6th.

Ocugen Trading Up 10.4 %

OCGN stock opened at $0.80 on Thursday. Ocugen has a one year low of $0.52 and a one year high of $2.08. The company has a market capitalization of $233.47 million, a PE ratio of -4.44 and a beta of 3.88. The company’s 50 day moving average price is $0.67 and its two-hundred day moving average price is $0.84. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.58 and a current ratio of 2.58.

Hedge Funds Weigh In On Ocugen

Institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp boosted its stake in shares of Ocugen by 7.1% during the third quarter. State Street Corp now owns 15,824,517 shares of the company’s stock valued at $15,701,000 after purchasing an additional 1,047,896 shares during the period. Geode Capital Management LLC boosted its position in Ocugen by 4.9% during the 4th quarter. Geode Capital Management LLC now owns 6,588,407 shares of the company’s stock valued at $5,305,000 after buying an additional 309,853 shares during the period. Northern Trust Corp grew its holdings in Ocugen by 10.4% in the 4th quarter. Northern Trust Corp now owns 2,407,137 shares of the company’s stock worth $1,938,000 after acquiring an additional 227,150 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Ocugen in the fourth quarter valued at about $1,681,000. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Ocugen by 12.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 860,244 shares of the company’s stock valued at $692,000 after acquiring an additional 93,288 shares during the last quarter. 10.27% of the stock is currently owned by institutional investors.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.